Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 3/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29701327 | 1.00 | NAPRT (0.69) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| Hydrochloric Acid SCHEMBL2673018 | 0.98 | NAPRT (0.67) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| Pyrrole SCHEMBL28319277 | 0.91 | NAPRT (0.59) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| Tartaric Acid SCHEMBL29700138 | 0.88 | KDM4E (0.69) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| Cadaverine Tartrate SCHEMBL28144426 | 0.88 | KDM4E (0.69) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL23932686 | 0.85 | CYP1A2 (0.63) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL3253168 | 0.83 | NAPRT (0.74) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL7417227 | 0.83 | CYP1A2 (0.59) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL9484991 | 0.82 | NAPRT (0.53) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL29864463 | 0.82 | NAPRT (0.61) | NAPRTCYP1A2CYP3A4CYP2C9RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024154979-A2 | NOVEL HETEROCYCLIC COMPOUNDS | 주식회사 이노보테라퓨틱스 | 2024-07-25 | — | — | WO | claimed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | claimed |
| WO-2023088285-A1 | SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF | 深圳湾实验室 | 2023-05-25 | — | — | WO | claimed |
| EP-3921317-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-12-15 | — | — | EP | claimed |
| WO-2020161257-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | WO | claimed |
| EP-2729459-B1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | claimed |
| CN-106432233-B | The preparation method of N, N, 6- trimethyl -2- (4- aminomethyl phenyls) imidazo [1,2-a] pyridine -3- acetamides | 华东理工大学 | 2018-08-14 | — | — | CN | claimed |
| CN-107848974-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001064680-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | claimed |
| CN-1311796-A | Peptide antiangiogenic agents | ABBOTT LAB (US) | 2001-09-05 | — | — | CN | claimed |
| US-5891891-A | PARKINSON'S DISEASE, NERVOUD SYSTEM DISORDERS AND DEMENTIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1999-04-06 | — | — | US | claimed |
| CN-1183719-A | Use of imidazo [1, 2-a] pyridine -3 -acetamide derivs. for therapeutic treatment of neuropsychiatric syndromes associated with disfunction of neural circuits of basal ganglia | CLARENDON TRADE & INVESTMENT L (PT) | 1998-06-03 | — | — | CN | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
| EP-0060144-A2 | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | NAPRT 1911/4885CYP1A2 3600/4885CYP3A4 3835/4885 |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | NAPRT 2567/4885CYP1A2 3088/4885CYP3A4 3625/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | NAPRT 1022/4885CYP1A2 2404/4885CYP3A4 4287/4885 |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | NAPRT 1743/4885CYP1A2 314/4885CYP3A4 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.